Regulating Hepatic Lipids via FXR Agonism and the Treatment of Non-Alcoholic Fatty Liver Disease
Bradley Conn Background: Non-alcoholic fatty liver disease (NAFLD) is a progressive disease in which fat abnormally accumulates (steatosis) in the liver.1 NAFLD can progress to fibrosis, cirrhosis, hepatocellular carcinoma and potentially death.2 The prevalence of NAFLD in the general population is 25%, in individuals with Type 2 Diabetes it is…